Unknown PHASE2 INTERVENTIONAL 1-arm NCT05790200

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

A Phase II Clinical Study of Cadonilimab (AK104) Combined With Chemotherapy in the Treatment of PD-1 Inhibitor Resistant Nasopharyngeal Carcinoma

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions Nasopharyngeal Carcinoma

Interventions Cadonilimab

Updated 6 times since 2023 Last updated: Mar 27, 2023 Started: Apr 1, 2023 Primary completion: Sep 22, 2025 Completion: Sep 22, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05790200, this PHASE2 trial focuses on Nasopharyngeal Carcinoma and remains ongoing. Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, it has been updated 6 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Oct 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Aug 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Apr 2023 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Data source: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China